

# 빠르게 성장하는 약물감시 SaaS 리더



**MERGERSCORP**

## SaaS

방갈로르에 본사를 두고 미국, 영국, 유럽에 지사를 두고 있는 빠르게 성장하는 클라우드 네이티브 SaaS 회사로, 글로벌 생명과학 산업을 위한 약물감시(PV) 및 임상시험 IT 솔루션을 전문으로 합니다. 이 회사는 접수, 사례 처리, 규제 제출, 신호 감지를 결합한 올인원 플랫폼을 제공하여 IT 비용을 최대 70%까지 절감하고 규정 준수 시간을 30%까지 단축합니다.

2017년에 설립된 이 회사는 인도에 65명 이상의 직원으로 구성된 도메인 전문 팀을 보유하고 있으며, 15개국 이상에서 100개 이상의 직접 고객과 160개 이상의 최종 고객을 지원하고 있습니다.

### 핵심 플랫폼 기능

- AS2 게이트웨이를 통한 통합 PV 데이터베이스
- 웹, 이메일 및 MICC 수신 모듈
- 사례 처리, 자동 내러티브, 신호 감지
- E2B R2/R3 지원 및 실시간 분석
- 통합 CTMS, EDC, eTMF, ePRO, IWRS 및 eConsent 모듈

### 차별화

- 사례 예약, 분류 및 처리를 위한 AI 기반 자동화
- 엔드투엔드 통합 시스템(레거시 스택의 파편화된 도구와 비교)
- 내장된 규정 준수 도구(예: 제출, 보고)
- 인도 10대 제약사 중 상위 3개사가 신뢰하는 기업

### 전략적 발자국

#### TARGET PRICE

\$ 0

#### GROSS REVENUE

\$ 3,000,000

#### EBITDA

\$ 1,000,000

#### BUSINESS TYPE

소프트웨어 및 SAAS

#### COUNTRY

인도

#### BUSINESS ID

L#20250961

- 인도, 미국, 영국 및 더 넓은 유럽에서 강력한 입지를 확보하고 있습니다.
- 글로벌 CRO에 포함 및 파트너십을 통한 확장(예: Wipro, Persistent, Cognizant)
- 250개 이상의 임상 연구에서 활발히 사용

## 비전

- 2025: AI 주도의 약물감시 워크플로 자동화
- 2030: 시장 점유율 30%를 차지하는 글로벌 톱 10 태양광 IT 공급업체로 도약하기

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

## MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

**MERGERSCORP**

[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)